NCT05148871View on ClinicalTrials.gov

Australian Phase 2b Study to Assess Effect of Dose Interval on Spikogen Covid-19 Vaccine

PHASE2/PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

March 1, 2022

Primary Completion Date

February 23, 2023

Study Completion Date

October 6, 2024

Conditions
COVID-19
Interventions
BIOLOGICAL

Spikogen/Covax-19

Spikogen/Covax-19 is a recombinant spike protein vaccine formulated with Advax-CpG55.2 adjuvant

Trial Locations (1)

5042

ARASMI, Adelaide

Sponsors

Collaborators (1)

Cinnagen
All Listed Sponsors
collaborator

Australian Respiratory and Sleep Medicine Institute

OTHER

collaborator

Cinnagen

INDUSTRY

lead

Vaxine Pty Ltd

INDUSTRY